Denintuzumab Mafodotin
Denintuzumab Mafodotin Uses, Dosage, Side Effects, Food Interaction and all others data.
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Selectively targets cancer cells expressing mutant epidermal growth factor receptor (EGFR) vIII or over expressing wild type EGFR . Denintuzumab Mafodotin acts on these cells to inhibit microtuble polymerization thus disrupting mitosis and vesicular trafficking
| Trade Name | Denintuzumab Mafodotin |
| Generic | Depatuxizumab mafodotin |
| Depatuxizumab mafodotin Other Names | Denintuzumab mafodotin, Depatuxizumab mafodotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
No approved indication.
How Denintuzumab Mafodotin works
Depatuxizumab is a chimeric monoclonal antibody for EGFR which is linked to monomethyl aurastatin F via a maleimidocaproyl linker (mafodotin) . Once delivered to the cancer cell, the mafodotin component is able to bind to tubulin and inhibit the exchange of GDP for GTP necessary for the polymerization of tubulin subunits to form microtubules. The inhibition of microtubule polymerization disrupts mitosis and interferes with vesicle trafficking in the cancer cell .
Innovators Monograph
You find simplified version here Denintuzumab Mafodotin
